French Pharma Industry Lays Out Wishlist For New Government, Proposes Five-Year Pact
The French pharmaceutical industry association is cautiously optimistic that the new government will take a longer-term view of the industry’s contribution to healthcare, and has proposed a pact setting out the relations between the industry and the state.
You may also be interested in...
Sales growth is slowing, innovation is being impaired, and prices remain constrained in France, says the industry body Leem. It has called on the government to take urgent action to remedy the situation.
Emmanuel Macron, who will be sworn in as the new French president on May 14, is likely to promulgate pro-industry policies, although he has warned that innovation in medicines must come at a “fair price.”
The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.